bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Legends and Figures from A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Authors: Arena Sabrina , Corti Giorgio , Durinikova Erika , Montone Monica , Reilly Nicole M. , Russo Mariangela , Lorenzato Annalisa , Arcella Pamela , Lazzari Luca , Rospo Giuseppe , Pagani Massimiliano , Cancelliere Carlotta , Negrino Carola , Isella Claudio , Bartolini Alice , Cassingena Andrea , Amatu Alessio , Mauri Gianluca , Sartore-Bianchi Andrea , Mittica Gloria , Medico Enzo , Marsoni Silvia , Linnebacher Michael , Abrignani Sergio , Siena Salvatore , Di Nicolantonio Federica , Bardelli Alberto
Published: April 2023

Supplementary Legends and Figures
Figure S6 from The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
Authors: Makohon-Moore Alvin P. , Lipson Evan J. , Hooper Jody E. , Zucker Amanda , Hong Jungeui , Bielski Craig M. , Hayashi Akimasa , Tokheim Collin , Baez Priscilla , Kappagantula Rajya , Kohutek Zachary , Makarov Vladimir , Riaz Nadeem , Postow Michael A. , Chapman Paul B. , Karchin Rachel , Socci Nicholas D. , Solit David B. , Chan Timothy A. , Taylor Barry S. , Topalian Suzanne L. , Iacobuzio-Donahue Christine A.
Published: April 2023

Figure S6 shows phylogenies based on point mutations with UV signature mutations removed.
Supplemental Table 1 from Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Authors: Aggen David H. , Ager Casey R. , Obradovic Aleksandar Z. , Chowdhury Nivedita , Ghasemzadeh Ali , Mao Wendy , Chaimowitz Matthew G. , Lopez-Bujanda Zoila A. , Spina Catherine S. , Hawley Jessica E. , Dallos Matthew C. , Zhang Cheng , Wang Vinson , Li Hu , Guo Xinzheng V. , Drake Charles G.
Published: April 2023

Clusters from Intratumoral Immunocytes by Spectral Cytometry.
Figure S4 from The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
Authors: Makohon-Moore Alvin P. , Lipson Evan J. , Hooper Jody E. , Zucker Amanda , Hong Jungeui , Bielski Craig M. , Hayashi Akimasa , Tokheim Collin , Baez Priscilla , Kappagantula Rajya , Kohutek Zachary , Makarov Vladimir , Riaz Nadeem , Postow Michael A. , Chapman Paul B. , Karchin Rachel , Socci Nicholas D. , Solit David B. , Chan Timothy A. , Taylor Barry S. , Topalian Suzanne L. , Iacobuzio-Donahue Christine A.
Published: April 2023

Figure S4 shows mutation signatures identified using Palimpsest.
Supplemental Figure 5 from Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses
Authors: Aggen David H. , Ager Casey R. , Obradovic Aleksandar Z. , Chowdhury Nivedita , Ghasemzadeh Ali , Mao Wendy , Chaimowitz Matthew G. , Lopez-Bujanda Zoila A. , Spina Catherine S. , Hawley Jessica E. , Dallos Matthew C. , Zhang Cheng , Wang Vinson , Li Hu , Guo Xinzheng V. , Drake Charles G.
Published: April 2023

Visualization of select RNA transcripts across treatment groups.
Figure S7 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S7. The correlation of GATA1 expression with clinical and morphological characteristics. (A-B) The spearman's correlation between the BM blast percentages and GATA1 expression. (C-D) The spearman's correlation between the median number of megakaryocytes per smear and GATA1 expression. The pairwise P-value is calculated using the Wilcoxon test, and Kruskal-Wallis test is used for intergroup multiple comparisons. BM, bone marrow.
Figure S17 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S17. External validation of the GSE6891 cohort. (A) The upper panel shows the expression patterns of 9 APL9-related genes from eight GSE6891 patients with APL. The bottom panel shows the bar plot of the APL9 score in ascending order. (B) Kaplan-Meier estimates of overall survival according to the APL9 score groups in GSE6891 cohort. P-value is calculated using the log-rank test.
Supplementary Figure S7 from Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Authors: Hitchman Tyler D. , Bayshtok Gabriella , Ceraudo Emilie , Moore Amanda R. , Lee Cindy , Jia Ruobing , Wang Naitao , Pachai Mohini R. , Shoushtari Alexander N. , Francis Jasmine H. , Guan Youxin , Chen Juliet , Chang Matthew T. , Taylor Barry S. , Sakmar Thomas P. , Huber Thomas , Chi Ping , Chen Yu
Published: April 2023

raw uncropped labeled western blots
Supplementary Table S4 from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers
Authors: Parikh Aparna R. , Mojtahed Amikasra , Schneider Jaime L. , Kanter Katie , Van Seventer Emily E. , Fetter Isobel J. , Thabet Ashraf , Fish Madeleine G. , Teshome Bezaye , Fosbenner Kathryn , Nadres Brandon , Shahzade Heather A. , Allen Jill N. , Blaszkowsky Lawrence S. , Ryan David P. , Giantonio Bruce , Goyal Lipika , Nipp Ryan D. , Roeland Eric , Weekes Colin D. , Wo Jennifer Y. , Zhu Andrew X. , Dias-Santagata Dora , Iafrate A. John , Lennerz Jochen K. , Hong Theodore S. , Siravegna Giulia , Horick Nora , Clark Jeffrey W. , Corcoran Ryan B.
Published: April 2023

Supplementary Table S4
Figure S1 from Integration of Genomic and Transcriptomic Markers Improves the Prognosis Prediction of Acute Promyelocytic Leukemia
Authors: Lin Xiaojing , Qiao Niu , Shen Yang , Fang Hai , Xue Qing , Cui Bowen , Chen Li , Zhu Hongming , Zhang Sujiang , Chen Yu , Jiang Lu , Wang Shengyue , Li Junmin , Wang Bingshun , Chen Bing , Chen Zhu , Chen Saijuan
Published: April 2023

Figure S1. Kaplan-Meier plot of clinical outcomes in consolidation arms with or without ATO. Kaplan-Meier estimates of overall survival (A), event-free survival (B), and disease-free survival (C) in accordance with the consolidation arms with or without ATO. P-value is calculated using the log-rank test.
Supplementary Table S1 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Authors: Chen Jingwei , Nelson Christopher , Wong Matthew , Tee Andrew E. , Liu Pei Y. , La Ting , Fletcher Jamie I. , Kamili Alvin , Mayoh Chelsea , Bartenhagen Christoph , Trahair Toby N. , Xu Ning , Jayatilleke Nisitha , Wong Marie , Peng Hui , Atmadibrata Bernard , Cheung Belamy B. , Lan Qing , Bryan Tracy M. , Mestdagh Pieter , Vandesompele Jo , Combaret Valerie , Boeva Valentina , Wang Jenny Y. , Janoueix-Lerosey Isabelle , Cowley Mark J. , MacKenzie Karen L. , Dolnikov Alla , Li Jinyan , Polly Patsie , Marshall Glenn M. , Reddel Roger R. , Norris Murray D. , Haber Michelle , Fischer Matthias , Zhang Xu D. , Pickett Hilda A. , Liu Tao
Published: April 2023

Supplementary Table S1. Primary screening of the Food and Drug Administration-Approved Oncology Drugs (AODs) Set IV from the US National Cancer Institute for BET bromodomain inhibitor enhancers.
Supplementary Figure S9 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

Study summary.
Supplementary Figure S4 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Authors: Chen Jingwei , Nelson Christopher , Wong Matthew , Tee Andrew E. , Liu Pei Y. , La Ting , Fletcher Jamie I. , Kamili Alvin , Mayoh Chelsea , Bartenhagen Christoph , Trahair Toby N. , Xu Ning , Jayatilleke Nisitha , Wong Marie , Peng Hui , Atmadibrata Bernard , Cheung Belamy B. , Lan Qing , Bryan Tracy M. , Mestdagh Pieter , Vandesompele Jo , Combaret Valerie , Boeva Valentina , Wang Jenny Y. , Janoueix-Lerosey Isabelle , Cowley Mark J. , MacKenzie Karen L. , Dolnikov Alla , Li Jinyan , Polly Patsie , Marshall Glenn M. , Reddel Roger R. , Norris Murray D. , Haber Michelle , Fischer Matthias , Zhang Xu D. , Pickett Hilda A. , Liu Tao
Published: April 2023

Supplementary Figure S4. Combination of the BET bromodomain inhibitor I-BET762 and chemotherapy agents, but not proteasome inhibitors, induces cytotoxicity to normal cells.
Supplementary Figure S3 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

Immunohistochemistry identifies AGRN and TIMP1 as candidate biomarkers to detect early changes in colorectal polyps.
Supplementary Figure S1 from Targeted Therapy of TERT-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy
Authors: Chen Jingwei , Nelson Christopher , Wong Matthew , Tee Andrew E. , Liu Pei Y. , La Ting , Fletcher Jamie I. , Kamili Alvin , Mayoh Chelsea , Bartenhagen Christoph , Trahair Toby N. , Xu Ning , Jayatilleke Nisitha , Wong Marie , Peng Hui , Atmadibrata Bernard , Cheung Belamy B. , Lan Qing , Bryan Tracy M. , Mestdagh Pieter , Vandesompele Jo , Combaret Valerie , Boeva Valentina , Wang Jenny Y. , Janoueix-Lerosey Isabelle , Cowley Mark J. , MacKenzie Karen L. , Dolnikov Alla , Li Jinyan , Polly Patsie , Marshall Glenn M. , Reddel Roger R. , Norris Murray D. , Haber Michelle , Fischer Matthias , Zhang Xu D. , Pickett Hilda A. , Liu Tao
Published: April 2023

Supplementary Figure S1. TERT induces TERT-rearranged neuroblastoma cell proliferation and cell cycle progression through a telomerase-independent mechanism.
Supplementary Figure S10 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

Inter-observer variability among fifty-five community pathologists.
Supplementary Figure S1 from Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions
Authors: Rickelt Steffen , Condon Charlene , Mana Miyeko , Whittaker Charlie , Pfirschke Christina , Roper Jatin , Patil Deepa T. , Brown Ian , Mattia Anthony R. , Zukerberg Lawrence , Zhao Qing , Chetty Runjan , Lauwers Gregory Y. , Neyaz Azfar , Leijssen Lieve G.J. , Boylan Katherine , Yilmaz Omer H. , Deshpande Vikram , Hynes Richard O.
Published: April 2023

Clustering analysis to identify extracellular matrix genes in individual colonic polyp samples.
Supplementary table 3 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental Table 3: Analysis of immunostaining of SSTR2 in tumor-derived from mice xenografts. Score 0-no staining, Score 1-positive staining in <25% of cells, Score 2-positive staining in 25-50% of cells, Score 3-positive staining in >50% of cells.
Supplementary Figure 3 from 177Lu-DOTA-EB-TATE, a Radiolabeled Analogue of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer
Authors: Thakur Shilpa , Daley Brianna , Millo Corina , Cochran Craig , Jacobson Orit , Lu Huiyan , Wang Zhantong , Kiesewetter Dale , Chen Xiaoyuan , Vasko Vasyl , Klubo-Gwiezdzinska Joanna
Published: April 2023

Supplemental figure 3: VAC inhibits cell proliferation by promoting cell cycle arrest and apoptosis. (A, D, G, J) VAC treatment (2 mM and 4 mM) inhibits cellular proliferation of FTC133 (n=3), BCPAP (n=3), TT (n=3) and AR42J (n=3) cells. ***p<0.001; **p<0.01. C-control; VAC-valproic acid. (B, E, H, K) VAC treatment (2 mM and 4 mM) leads to cell cycle arrest of FTC133 (n=3), BCPAP (n=3), TT (n=3) and AR42J (n=3) cells. C-control; VAC-valproic acid. (C, F, I, L) VAC treatment (2 mM and 4 mM) promotes apoptosis of FTC133 (n=3), BCPAP (n=3), TT (n=3) and AR42J (n=3) cells, respectively. C-control; VAC-valproic acid.
Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
Authors: Cho Hyunsoo , Kim Kyung Hwan , Lee Hoyoung , Kim Chang Gon , Chung Haerim , Choi Yoon Seok , Park Su-Hyung , Cheong June-Won , Min Yoo Hong , Shin Eui-Cheol , Kim Jin Seok
Published: April 2023

Supplementary Figures 1-11
Supplementary Data from Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma
Authors: Cho Hyunsoo , Kim Kyung Hwan , Lee Hoyoung , Kim Chang Gon , Chung Haerim , Choi Yoon Seok , Park Su-Hyung , Cheong June-Won , Min Yoo Hong , Shin Eui-Cheol , Kim Jin Seok
Published: April 2023

Supplementary Tables 1-2
Supplementary Table S6 from Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma
Authors: Holt Jeremiah , Walter Vonn , Yin Xiaoying , Marron David , Wilkerson Matthew D. , Choi Hyo Young , Zhao Xiaobei , Jo Heejoon , Hayes David Neil , Ko Yoon Ho
Published: April 2023

Mutation frequency of top 50 cancer related genes in HNSCC miRNA subclasses.
Supplementary Legend from Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Authors: Jiffry Jeeshan , Thavornwatanayong Thongthai , Rao Devika , Fogel Elisha J. , Saytoo Durvanand , Nahata Rishika , Guzik Hillary , Chaudhary Imran , Augustine Titto , Goel Sanjay , Maitra Radhashree
Published: April 2023

Supplementary Legend
Supplementary Data from Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Authors: Kantarjian Hagop M. , Stock Wendy , Cassaday Ryan D. , DeAngelo Daniel J. , Jabbour Elias , O'Brien Susan M. , Stelljes Matthias , Wang Tao , Paccagnella M. Luisa , Nguyen Kevin , Sleight Barbara , Vandendries Erik , Neuhof Alexander , Laird A. Douglas , Advani Anjali S.
Published: April 2023

Supplementary Data
Supplementary Data from A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma
Authors: Demajo Santiago , Albero Robert , Clot Guillem , Castellano Giancarlo , Navarro Alba , Capdevila Cristina , Enjuanes Anna , Nadeu Ferran , Giné Eva , Pinyol Magda , Jaffe Elaine S. , Ott German , Staudt Louis M. , Rosenwald Andreas , Scott David W. , Rimsza Lisa M. , López-Guillermo Armando , Beà Sílvia , Campo Elias , Jares Pedro
Published: April 2023

Supplementary Methods, Supplementary Tables S1-S5, and Supplementary Figures S1-S15
Figure S19 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Examples of 3D PET images and corresponding heatmaps
Table S5 from Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Authors: Adib Elio , Klonowska Katarzyna , Giannikou Krinio , Do Khanh T. , Pruitt-Thompson Solida , Bhushan Ketki , Milstein Matthew I. , Hedglin Jennifer , Kargus Katherine E. , Sholl Lynette M. , Tsuji Junko , Hyman David M. , Sisk Anne , Shapiro Geoffrey I. , Vargas Hebert A. , Harding James J. , Voss Martin H. , Iyer Gopa , Kwiatkowski David J.
Published: April 2023

Table S5. Nonsynonymous single nucleotide variants (SNVs) and insertions/deletions (indels) identified by whole exome sequencing (WES) and/or initial panel sequencing. Each sheet is a different tumor sample.
Figure S15 from Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Authors: Cheng Nai-Ming , Yao Jiawen , Cai Jinzheng , Ye Xianghua , Zhao Shilin , Zhao Kui , Zhou Wenlan , Nogues Isabella , Huo Yuankai , Liao Chun-Ta , Wang Hung-Ming , Lin Chien-Yu , Lee Li-Yu , Xiao Jing , Lu Le , Zhang Ling , Yen Tzu-Chen
Published: April 2023

Time-dependent ROC analyses, 2-year survival, DeepPET-OPSCC score, clinical factors, nomograms, discovery and TCIA test cohorts
Supplementary figure SF4 from Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer
Authors: Turner Philip G. , Jain Suneil , Cole Aidan , Grey Arthur , Mitchell Darren , Prise Kevin M. , Hounsell Alan R. , McGarry Conor K. , Biggart Sandra , O'Sullivan Joe M.
Published: April 2023

Supplementary figure SF4 shows (A) Kaplan-Meier plot to estimate median progression free survival as time from first docetaxel (or trial registration if no docetaxel received) until PSA progression per PCWG. Median progression free survival = 20.5 months. (B) Kaplan Meier plot to estimate median overall survival as time from first docetaxel (or trial registration if no docetaxel received) until death. Median not reached.
Figure S1 from A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer
Authors: Shafique Michael R. , Fisher Terrence L. , Evans Elizabeth E. , Leonard John E. , Pastore Desa Rae E. , Mallow Crystal L. , Smith Ernest , Mishra Vikas , Schröder Andreas , Chin Kevin M. , Beck Joseph T. , Baumgart Megan A. , Govindan Ramaswamy , Gabrail Nashat Y. , Spira Alexander I. , Seetharamu Nagashree , Lou Yanyan , Mansfield Aaron S. , Sanborn Rachel E. , Goldman Jonathan W. , Zauderer Maurice
Published: April 2023

Consort diagram
Supplementary Table S2 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

Univariate and multivariate analyses of PFS according to TMB and clinical features
Supplementary Figure S3 from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

PTEN-positive tumor and the expression of PTEN mRNA according to PTEN mutations
Supplementary Figure Legends from A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors
Authors: Chida Keigo , Kawazoe Akihito , Kawazu Masahito , Suzuki Toshihiro , Nakamura Yoshiaki , Nakatsura Tetsuya , Kuwata Takeshi , Ueno Toshihide , Kuboki Yasutoshi , Kotani Daisuke , Kojima Takashi , Taniguchi Hiroya , Mano Hiroyuki , Ikeda Masafumi , Shitara Kohei , Endo Itaru , Yoshino Takayuki
Published: April 2023

Supplementary Figure Legends
Supplementary Figure S6 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S6 shows the comparative analyses of surface biomarker and gene expression of CD103+/- and CD39+/- subpopulations between CD8+ and CD4+ TILs.
Supplementary Figure S5 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S5 shows tSNE projections of immunoregulatory factors on CD45 positive immune cell compartment in HGSC tumor samples.
Supplementary Figure S14 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S14 shows the extent of TCR overlap between T-cell subsets isolated from primary HGSC tumor samples.
Supplementary Figure S11 from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

Supplementary Figure S11 shows the expression level of genes encoding cytolytic molecules in CD8 clusters and the expression level of genes associated with tumor-infiltrating Treg in Treg clusters.
Supplementary Data from Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Authors: Laumont Céline M. , Wouters Maartje C.A. , Smazynski Julian , Gierc Nicole S. , Chavez Elizabeth A. , Chong Lauren C. , Thornton Shelby , Milne Katy , Webb John R. , Steidl Christian , Nelson Brad H.
Published: April 2023

List of Supplementary Figures and Tables, Supplementary Methods, and Supplementary References
Supplemental Figure 4 from Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
Authors: Nagle Veronica L. , Henry Kelly E. , Hertz Charli Ann J. , Graham Maya S. , Campos Carl , Parada Luis F. , Pandit-Taskar Neeta , Schietinger Andrea , Mellinghoff Ingo K. , Lewis Jason S.
Published: April 2023

[64Cu]Cu-NOTA-anti-CD8 Uptake in PDX 160615-1. Coregistered PET/CT images of + PBMCs GBM PDX 160615-1 at 24 hours following [64Cu]Cu-NOTA-anti-CD8 tracer injection (n = 5). IHC for human CD8, H&E and autoradiography (n = 3/condition) of PDX 160615-1.
Supplemental Figure 2 from Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
Authors: Nagle Veronica L. , Henry Kelly E. , Hertz Charli Ann J. , Graham Maya S. , Campos Carl , Parada Luis F. , Pandit-Taskar Neeta , Schietinger Andrea , Mellinghoff Ingo K. , Lewis Jason S.
Published: April 2023

PET/CT of [64Cu]Cu-NOTA-anti-CD8 in Non-HIS and Non-Tumor-Bearing Controls in PDX 160721-1. Representative co-registered PET/CT images of + Tumor - PBMC and - Tumor + PBMC NOG CIEA mouse brains 24 h following [64Cu]Cu-NOTA-anti-CD8 tracer injection (n = 3/condition).
Supplementary Table 2 from Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer
Authors: Guardia Cristina , Bianchini Giampaolo , Arpí-LLucià Oriol , Menendez Silvia , Casadevall David , Galbardi Barbara , Dugo Matteo , Servitja Sonia , Montero Juan Carlos , Soria-Jiménez Luis , Sabbaghi MohammadA , Peña Raul , Madoz-Gúrpide Juan , Lloveras Belen , Lluch Ana , Eroles Pilar , Arribas Joaquin , Pandiella Atanasio , Gianni Luca , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Supplementary Table 2 shows main clinical-pathological characteristics of HER2-positive breast cancer patient's cohort treated with neoadjuvant-based therapy and the association of NRG1 protein expression with the diverse clinical parameters analysed.
Figure S7 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S7
Figure S6 from Non-invasive Detection of Immunotherapy-Induced Adverse Events
Authors: Ferreira Carolina A. , Heidari Pedram , Ataeinia Bahar , Sinevici Nicoleta , Sise Meghan E. , Colvin Robert B. , Wehrenberg-Klee Eric , Mahmood Umar
Published: April 2023

Supplementary Figure S6
Figure S2 from Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study
Authors: Morris Michael J. , Rowe Steven P. , Gorin Michael A. , Saperstein Lawrence , Pouliot Frédéric , Josephson David , Wong Jeffrey Y.C. , Pantel Austin R. , Cho Steve Y. , Gage Kenneth L. , Piert Morand , Iagaru Andrei , Pollard Janet H. , Wong Vivien , Jensen Jessica , Lin Tess , Stambler Nancy , Carroll Peter R. , Siegel Barry A.
Published: April 2023

Participant Flow
Table S1 from Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
Authors: Suzuki Mikiko , Yagishita Shigehiro , Sugihara Kiyoshi , Ogitani Yusuke , Nishikawa Tadaaki , Ohuchi Mayu , Teishikata Takashi , Jikoh Takahiro , Yatabe Yasushi , Yonemori Kan , Tamura Kenji , Hasegawa Kosei , Hamada Akinobu
Published: April 2023

HER2 expression level of each cell line as assessed by standard scoring method and H-Score
Supplementary Data from HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer
Authors: Hasanali Sarrah L. , Morera Daley S. , Racine Ronny R. , Hennig Martin , Ghosh Santu , Lopez Luis E. , Hupe Marie C. , Escudero Diogo O. , Wang Jiaojiao , Zhu Huabin , Sarcan Semih , Azih Ijeoma , Zhou Michael , Jordan Andre R. , Terris Martha K. , Kuczyk Markus A. , Merseburger Axel S. , Lokeshwar Vinata B.
Published: April 2023

Hasanali et al Supplementary Materials
Figure S2 from Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer
Authors: Marshall Catherine H. , Fu Wei , Wang Hao , Park Jong Chul , DeWeese Theodore L. , Tran Phuoc T. , Song Daniel Y. , King Serina , Afful Michaella , Hurrelbrink Julia , Manogue Charlotte , Cotogno Patrick , Moldawer Nancy P. , Barata Pedro C. , Drake Charles G. , Posadas Edwin M. , Armstrong Andrew J. , Sartor Oliver , Antonarakis Emmanuel S.
Published: April 2023

Figure S2
Table S3 from An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
Authors: Bai Yalai , Cole Kimberly , Martinez-Morilla Sandra , Ahmed Fahad Shabbir , Zugazagoitia Jon , Staaf Johan , Bosch Ana , Ehinger Anna , Nimeus Emma , Hartman Johan , Acs Balazs , Rimm David L.
Published: April 2023

Cox regression analysis of TIL variables for OS in all available cohorts
Figure S2 from An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
Authors: Bai Yalai , Cole Kimberly , Martinez-Morilla Sandra , Ahmed Fahad Shabbir , Zugazagoitia Jon , Staaf Johan , Bosch Ana , Ehinger Anna , Nimeus Emma , Hartman Johan , Acs Balazs , Rimm David L.
Published: April 2023

Validation of QuPath TIL algorithms in TMA Yale1
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Smith Catherine C. , Viny Aaron D. , Massi Evan , Kandoth Cyriac , Socci Nicholas D. , Rapaport Franck , Najm Matthieu , Medina-Martinez Juan S. , Papaemmanuil Elli , Tarver Theodore C. , Hsu Henry H. , Le Mai H. , West Brian , Bollag Gideon , Taylor Barry S. , Levine Ross L. , Shah Neil P.
Published: April 2023

Supplemental Figures
Supplementary Tables from BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression
Authors: Warner Evan , Herberts Cameron , Fu Simon , Yip Steven , Wong Amanda , Wang Gang , Ritch Elie , Murtha Andrew J. , Vandekerkhove Gillian , Fonseca Nicolette M. , Angeles Arkhjamil , Beigi Arshia , Schönlau Elena , Beja Kevin , Annala Matti , Khalaf Daniel , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Tables S1-S10
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Smith Catherine C. , Viny Aaron D. , Massi Evan , Kandoth Cyriac , Socci Nicholas D. , Rapaport Franck , Najm Matthieu , Medina-Martinez Juan S. , Papaemmanuil Elli , Tarver Theodore C. , Hsu Henry H. , Le Mai H. , West Brian , Bollag Gideon , Taylor Barry S. , Levine Ross L. , Shah Neil P.
Published: April 2023

Table S3
Table S2 from Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Authors: Li Dapeng , Chi Yihebali , Chen Xiaohong , Ge Minghua , Zhang Yuan , Guo Zhuming , Wang Jun , Chen Jie , Zhang Jiewu , Cheng Ying , Li Zhendong , Liu Hui , Qin Jianwu , Zhu Jingqiang , Cheng Ruochuan , Xu Zhengang , Zheng Xiangqian , Tang Pingzhang , Gao Ming
Published: April 2023

Changes of serum calcitonin level (ng/L) during treatment
Figure S2 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Authors: Mehrvarz Sarshekeh Amir , Alshenaifi Jumanah , Roszik Jason , Manyam Ganiraju C. , Advani Shailesh M. , Katkhuda Riham , Verma Anuj , Lam Michael , Willis Jason , Shen John Paul , Morris Jeffrey , Davis Jennifer S. , Loree Jonathan M. , Lee Hey Min , Ajani Jaffer A. , Maru Dipen M. , Overman Michael J. , Kopetz Scott
Published: April 2023

Supplementary Fig S2: Association of gene size and the fold increase in the frame-shift mutation rate of cases with MSS CRC.
Supplementary Figures 1-12 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases
Authors: Smalley Inna , Chen Zhihua , Phadke Manali , Li Jiannong , Yu Xiaoqing , Wyatt Clayton , Evernden Brittany , Messina Jane L. , Sarnaik Amod , Sondak Vernon K. , Zhang Chaomei , Law Vincent , Tran Nam , Etame Arnold , Macaulay Robert J.B. , Eroglu Zeynep , Forsyth Peter A. , Rodriguez Paulo C. , Chen Y. Ann , Smalley Keiran S.M.
Published: April 2023

Supplemental Figure 1. Expression of T, NK, B and Plasma cell markers by metastatic site. Supplemental Figure 2. Expression of myeloid cell markers by metastatic site and gene expression associated with classical and alternative macrophage activation. Supplemental Figure 3. Baseline and therapy induced changes in the LMM immune landscape. Supplemental Figure 4. Baseline and therapy-mediated changes to the MBM immune landscape. Supplemental Figure 5. Expression of MHC class I and II in melanoma cells from samples with and without DC3s. Supplemental Figure 6. Cell-cell interactions between DC3s and T cells defined by SingleCellR. Supplemental Figure 7. Detection of DC3 cells in clinical samples using multiplexed IHC. Supplemental Figure 8. Validation analysis of samples from melanoma metastases in a publicly available validation dataset. Supplemental Figure 9. Expression of key markers that distinguish the major subsets of myeloid cells. Supplemental Figure 10. Correlation of DC3 gene signature and PC loading for DC3 gene signature in TCGA. Supplemental Figure 11. Overall survival for melanoma patients with LMM metastases whose CSF samples contained high DC3 cells vs. low DC3 cells. Supplemental Figure 12. Correlation of individual genes from the DC3 gene signature to overall survival and their univariate cox proportional-hazards models in TCGA dataset.
Supplementary Figure S5 from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Authors: Zaccaria Gian Maria , Bertamini Luca , Petrucci Maria Teresa , Offidani Massimo , Corradini Paolo , Capra Andrea , Romano Alessandra , Liberati Anna Marina , Mannina Donato , de Fabritiis Paolo , Cascavilla Nicola , Ruggeri Marina , Mina Roberto , Patriarca Francesca , Benevolo Giulia , Belotti Angelo , Gaidano Gianluca , Nagler Arnon , Hájek Roman , Spencer Andrew , Sonneveld Pieter , Musto Pellegrino , Boccadoro Mario , Gay Francesca
Published: April 2023

Figure S5. OS from relapse (A) and 2nd PFS (B) in patients with ER18 vs. late relapse (LR)
Supplementary Data from BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression
Authors: Xing Lijie , Wang Su , Liu Jiye , Yu Tengteng , Chen Hailin , Wen Kenneth , Li Yuyin , Lin Liang , Hsieh Phillip A. , Cho Shih-Feng , An Gang , Qiu Lugui , Kinneer Krista , Munshi Nikhil , Anderson Kenneth C. , Tai Yu-Tzu
Published: April 2023

Supplementary materials
Supplementary Appendix from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Authors: Zaccaria Gian Maria , Bertamini Luca , Petrucci Maria Teresa , Offidani Massimo , Corradini Paolo , Capra Andrea , Romano Alessandra , Liberati Anna Marina , Mannina Donato , de Fabritiis Paolo , Cascavilla Nicola , Ruggeri Marina , Mina Roberto , Patriarca Francesca , Benevolo Giulia , Belotti Angelo , Gaidano Gianluca , Nagler Arnon , Hájek Roman , Spencer Andrew , Sonneveld Pieter , Musto Pellegrino , Boccadoro Mario , Gay Francesca
Published: April 2023

Supplementary Appendix: â€¢ SUPPLEMENTARY METHODS. iFISH; ER24 analysis; clinical endpoints; statistical analysis; â€¢ SUPPLEMENTARY RESULTS. ER24 analysis; DS-ERMM score - additional analyses; outcome after relapse in the ER18 analysis; â€¢ TABLE S1A. Treatment regimens in the source studies; â€¢ TABLE S1B. Eligibility criteria for clinical trials; â€¢ TABLE S2. Patient characteristics in the overall population and stratified according to the ER24 outcome as training set and validation set; â€¢ TABLE S3. Univariate (UV) and multivariate (MV) analyses of the baseline features to predict ER24; LIST OF SUPPLEMENTARY FIGURE FILES.
Supplementary Data from Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Authors: Jacobs Samuel A. , Lee James J. , George Thomas J. , Wade James L. , Stella Philip J. , Wang Ding , Sama Ashwin R. , Piette Fanny , Pogue-Geile Katherine L. , Kim Rim S. , Gavin Patrick G. , Lipchik Corey , Feng Huichen , Wang Ying , Finnigan Melanie , Kiesel Brian F. , Beumer Jan H. , Wolmark Norman , Lucas Peter C. , Allegra Carmen J. , Srinivasan Ashok
Published: April 2023

Supp Table 2
Supplementary Figure 9 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

Marker genes for Th, NK, and Treg cells
Figure S10 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Transcriptional adaptation in DP6 persistent cells
Figure S8 from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Authors: Ishida Yoshihiro , Kakiuchi Nobuyuki , Yoshida Kenichi , Inoue Yoshikage , Irie Hiroyuki , Kataoka Tatsuki R. , Hirata Masahiro , Funakoshi Takeru , Matsushita Shigeto , Hata Hiroo , Uchi Hiroshi , Yamamoto Yuki , Fujisawa Yasuhiro , Fujimura Taku , Saiki Ryunosuke , Takeuchi Kengo , Shiraishi Yuichi , Chiba Kenichi , Tanaka Hiroko , Otsuka Atsushi , Miyano Satoru , Kabashima Kenji , Ogawa Seishi
Published: April 2023

Validation of mutational signature analysis by an alternative analysis method
Figure S7 from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Authors: Ishida Yoshihiro , Kakiuchi Nobuyuki , Yoshida Kenichi , Inoue Yoshikage , Irie Hiroyuki , Kataoka Tatsuki R. , Hirata Masahiro , Funakoshi Takeru , Matsushita Shigeto , Hata Hiroo , Uchi Hiroshi , Yamamoto Yuki , Fujisawa Yasuhiro , Fujimura Taku , Saiki Ryunosuke , Takeuchi Kengo , Shiraishi Yuichi , Chiba Kenichi , Tanaka Hiroko , Otsuka Atsushi , Miyano Satoru , Kabashima Kenji , Ogawa Seishi
Published: April 2023

Phospho-AKT and phospho-ERK staining patterns of ERBB2/ERBB3 mutated cases
Figure S5 from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Authors: Ishida Yoshihiro , Kakiuchi Nobuyuki , Yoshida Kenichi , Inoue Yoshikage , Irie Hiroyuki , Kataoka Tatsuki R. , Hirata Masahiro , Funakoshi Takeru , Matsushita Shigeto , Hata Hiroo , Uchi Hiroshi , Yamamoto Yuki , Fujisawa Yasuhiro , Fujimura Taku , Saiki Ryunosuke , Takeuchi Kengo , Shiraishi Yuichi , Chiba Kenichi , Tanaka Hiroko , Otsuka Atsushi , Miyano Satoru , Kabashima Kenji , Ogawa Seishi
Published: April 2023

Copy number alterations landscape of EMPD reordered by recurrence status
Supplementary table 4 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Detailed summary of host genome somatic INDELs identified by targeted capture sequencing analysis of FFPE tumor specimens
Supplementary Figure S1 from Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma
Authors: Chahoud Jad , Gleber-Netto Frederico O. , McCormick Barrett Z. , Rao Priya , Lu Xin , Guo Ming , Morgan Maggaret B. , Chu Randy A. , Martinez-Ferrer Magaly , Eterovic Agda Karina , Pickering Curtis R. , Pettaway Curtis A.
Published: April 2023

Figure S1 - Oncogenic pathways enrichment among penile cancer samples. Each oncoplot represent the mutation distribution among PSCC samples for each of the 10 oncogenic signaling pathways (RTK/RAS pathway; Wnt pathway; Notch pathway; Hippo pathway; PI3K pathway; Cell cycle pathway; Myc pathway; TGFβ pathway; p53 pathway; and Nrf2 pathway) described by Sanchez-Vega et al. (2018). Each oncoplot represents the list of specific genes linked to pathways with major impact on cancer curated by Sanchez-Vega et al. (2018) that were found mutated in our PSCC samples. Colored squares indicate mutant samples and the respective gene. Red gene symbols indicate known oncogenes and blue gene symbols indicate known tumor suppressor genes. Patient distribution along the X-axis is the same observed in the oncoplot of the Figure 1.
Supplementary Data from Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Authors: Peddi Parvin F. , Fasching Peter A. , Liu Duan , Quinaux Emmanuel , Robert Nicholas J. , Valero Vicente , Crown John , Falkson Carla , Brufsky Adam , Cunningham Julie M. , Weinshilboum Richard M. , Pienkowski Tadeusz , Eiermann Wolfgang , Martín Miguel , Bee Valerie , Wang Xiaoyan , Wang Liewei , Yang Eric , Slamon Dennis J. , Hurvitz Sara A.
Published: April 2023

Supplementary Data from Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Supplementary Figures 1-12 and Tables S1-S2 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Authors: Hu Nan , Wang Fangyang , Sun Tianyu , Xu Zhengfan , Zhang Jing , Bernard Denzil , Xu Shilin , Wang Shaomeng , Kaminski Mark , Devata Suma , Phillips Tycel , Malek Sami N.
Published: April 2023

Fig. S1: BTK mutations detected in cDNA in five FL BTK mutant cases. Fig. S2:BTK mutations destabilize the mutant BTK proteins. Fig. S3:BTK mutations do not influence PLCÎ³2-1217 phosphorylation in reconstituted lymphoma cell lines. Fig. S4:BTK mutations do not influence PLCÎ³2-759 phosphorylation in reconstituted lymphoma cell lines Fig. S5:Preserved PLCÎ³2-1217 phosphorylation in OCI-LY7 BTK-/- BLK-/- cells. Fig. S6:PLCÎ³2-1217 or PLCÎ³2-759 phosphorylation in OCI-LY7 BTK-/- BLK-/- or SUDHL4 BTK-/- BLK-/- cells treated with kinase inhibitors. Fig. S7:BTK mutations enhance anti-IgM induced AKT308 phosphorylation Fig. S8: Acute inhibition of BTK by ibrutinib or acalabrutinib does not augment anti-Ig induced AKT phosphorylation Fig. S9: The proteolysis targeting chimera (PROTAC)-mediated degradation of BTK protein results in augmentation of sIG-crosslinking induced AKT phosphorylation. Fig. S10:Primary human FL B cells have augmented AKT phosphorylation following surface IgM crosslinking: Fig. S11: The augmented phosphorylation of AKT by BTK mutants following anti-Ig treatment is abolished by pre-treatment with a PI3KÎ' inhibitor (CAL101) Fig. S12: Effects of BTK mutations on ibrutinib sensitivities in HBL1 and TMD8 cell lines
Supplementary Figure S7 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

PKM2 analysis in TP459 neurospheres
Supplementary Figure S6 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Western blot analysis of PKM2 expression in IC-1
Supplementary Figure S4 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

[18F]DASA-23 time activity curves
Supplementary Figure Legends from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Figure Legends
Figure S2 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Authors: Angeles Christina V. , Velez Ana , Rios Jordan , Laxa Bernadette , Shum David , Ruiz Penelope D. , Shen Yawei , Ostrovnaya Irina , Gularte-Mérida Rodrigo , Nacev Benjamin A. , Dickson Mark A. , Djaballah Hakim , Okada Tomoyo , Singer Samuel
Published: April 2023

SN-38 inhibits cell viability and increases expression of C/EBPï�¡ in the nucleus in DDLS cells.
Supplementary Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Authors: Toulmonde Maud , Brahmi Mehdi , Giraud Antoine , Chakiba Camille , Bessede Alban , Kind Michèle , Toulza Emilie , Pulido Marina , Albert Sabrina , Guégan Jean-Philippe , Cousin Sophie , Mathoulin-Pelissier Simone , Perret Raul , Croce Sabrina , Blay Jean-Yves , Ray-Coquard Isabelle , Floquet Anne , Italiano Antoine
Published: April 2023

Supplementary Data from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Supplementary Figure S4 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
Authors: Obradovic Aleksandar , Graves Diana , Korrer Michael , Wang Yu , Roy Sohini , Naveed Abdullah , Xu Yaomin , Luginbuhl Adam , Curry Joseph , Gibson Michael , Idrees Kamran , Hurley Paula , Jiang Peng , Liu X. Shirley , Uppaluri Ravindra , Drake Charles G. , Califano Andrea , Kim Young J.
Published: April 2023

Supplementary Figure S4 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer